120 related articles for article (PubMed ID: 37827949)
1. Re: Raghav Gupta, Adriana M. Pedraza, Michael A. Gorin, Ashutosh K. Tewari. Defining the Role of Large Language Models in Urologic Care and Research. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.017.
Kleebayoon A; Wiwanitkit V
Eur Urol Oncol; 2024 Jun; 7(3):633. PubMed ID: 37827949
[No Abstract] [Full Text] [Related]
2. Re: Pawel Rajwa, Daniele Robesti, Michael Chaloupka, et al. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.006.
Onal C; Elmali A; Cem Guler O
Eur Urol Oncol; 2024 Jun; 7(3):644-645. PubMed ID: 38365504
[No Abstract] [Full Text] [Related]
3. Re: Kristian D. Stensland, Harras Zaid, Mark Broadwin, et al. Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2018.11.003.
Moschini M; Zamboni S; Mattei A
Eur Urol Oncol; 2019 Mar; 2(2):230. PubMed ID: 31017104
[No Abstract] [Full Text] [Related]
4. Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [
Guidotti A; Lombardo R; De Nunzio C
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38570238
[No Abstract] [Full Text] [Related]
5. Re: Ost P, Siva S, Brabrand S, et al. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007.
Montorsi F; Gandaglia G; Barletta F; Briganti A
Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38418265
[No Abstract] [Full Text] [Related]
6. Re: Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread with Poor Prognosis. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.005.
Bandini M; Salonia A; Montorsi F
Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38472030
[No Abstract] [Full Text] [Related]
7. Re: Karim A. Touijer, Daniel D. Sjoberg, Nicole Benfante, et al. Limited Versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.03.006.
Yang B; Yang G; Yao X
Eur Urol Oncol; 2021 Oct; 4(5):852-853. PubMed ID: 34535419
[No Abstract] [Full Text] [Related]
8. Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
Lombardo R; Riolo S; De Nunzio C
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37872030
[No Abstract] [Full Text] [Related]
9. Re: Guillaume Ploussard, Eric Barret, Gaëlle Fiard, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.01.019.
Lin FX; Yu Y; Xu ZP
Eur Urol Oncol; 2024 May; ():. PubMed ID: 38772750
[No Abstract] [Full Text] [Related]
10. Re: Hein V. Stroomberg, Signe Benzon Larsen, Torben Kjær Nielsen, J. Thomas Helgstrand, Klaus Brasso, Andreas Røder. Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.005.
Gallo G; Lombardo R; De Nunzio C
Eur Urol Oncol; 2024 Jun; 7(3):646-647. PubMed ID: 38290922
[No Abstract] [Full Text] [Related]
11. Reply to Marco Bandini, Andrea Salonia, and Francesco Montorsi's Letter to the Editor re: Laura Elst, Manon T.A. Vreeburg, Hielke Martijn de Vries, et al. Corporal Skip Metastases in Penile Squamous Cell Carcinoma: An Unknown and Distinct Pattern of Spread with Poor Prognosis. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.005.
Elst L; Vreeburg MTA; Brouwer OR; Albersen M
Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38493073
[No Abstract] [Full Text] [Related]
12. Re: Felix Seelemeyer, David Pfister, Robert Pappesch, et al. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021.
Urabe F; Yoshioka T; Kimura T
Eur Urol Oncol; 2024 Apr; 7(2):307. PubMed ID: 38238224
[No Abstract] [Full Text] [Related]
13. Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Piet Ost, Shankar Siva, Sugmund Brabrand, et al. PEACE V-Salvage Treatment of Oligorecurrent Nodal Prostate Cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007.
Zilli T; Ost P
Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38418267
[No Abstract] [Full Text] [Related]
14. Reply to Riccardo Lombardo, Sara Riolo, and Cosimo De Nunzio's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
D'Andrea D; Soria F; Hurle R; Enikeev D; Kotov S; Régnier S; Xylinas E; Lusuardi L; Heidenreich A; Cai C; Frego N; Taraktin M; Ryabov M; Gontero P; Compérat E; Shariat SF;
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37865570
[No Abstract] [Full Text] [Related]
15. Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010.
Montorsi F; Rosiello G; Gandaglia G; Salonia A; Briganti A
Eur Urol Oncol; 2024 Jun; 7(3):636. PubMed ID: 37951819
[No Abstract] [Full Text] [Related]
16. Re: Steven MacLennan, Eilidh Duncan, Ted A. Skolarus, et al. Improving Guideline Adherence in Urology. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.10.007.
Montorsi F
Eur Urol Focus; 2022 Nov; 8(6):1867. PubMed ID: 35153171
[No Abstract] [Full Text] [Related]
17. Re: Kosuke Takemura, Matthew S. Ernst, Vishal Navani, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.002.
Ishiyama Y; Urabe F
Eur Urol Oncol; 2024 Jun; 7(3):642-643. PubMed ID: 38238222
[No Abstract] [Full Text] [Related]
18. Re: Mauro Gacci, Vasileios I. Sakalis, Markos Karavitakis, et al. European Association of Urology Guidelines on Male Urinary Incontinence. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.05.012.
Lv M; Luo X; Chen Y
Eur Urol; 2022 Oct; 82(4):e118. PubMed ID: 35961869
[No Abstract] [Full Text] [Related]
19. Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005.
Furrer MA; Wuethrich PY
Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37806852
[No Abstract] [Full Text] [Related]
20. Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005.
Montorsi F; Moschini M; Gandaglia G; Briganti A
Eur Urol Focus; 2023 Sep; ():. PubMed ID: 37748951
[No Abstract] [Full Text] [Related]
[Next] [New Search]
